GHRH-T44 and Sermorelin Research Guide: GHRH(1-44) vs GHRH(1-29)
GHRH-T44 and Sermorelin Research Guide: GHRH(1-44) vs GHRH(1-29)
A primary-source guide to full-length GHRH(1-44), shorter GHRH(1-29)/sermorelin, pituitary GHRH-receptor signaling, and identity-critical purchasing questions.
Forty-four residues and twenty-nine residues are not interchangeable
Native human growth-hormone-releasing hormone is a 44-residue hypothalamic peptide that activates the pituitary GHRH receptor. Human GHRH(1-44)-NH2 studies measured acute or short-term GH and IGF-I responses in healthy young men, older men, and other defined research populations.
Sermorelin is the shorter amidated GHRH(1-29) fragment. It engages the same receptor system but is a different molecule with its own dose-response and diagnostic literature. Neither GHRH form is the same as a ghrelin-receptor agonist such as ipamorelin.
GHRH-T44 appears to be a vendor shorthand rather than a universal literature name. Before matching a product to GHRH(1-44) papers, verify its full sequence, residue count, terminal chemistry, salt form, and observed molecular mass.
What researchers are trying to understand
Is GHRH-T44 the same as sermorelin?
No. GHRH(1-44)-NH2 contains 44 residues, while sermorelin is GHRH(1-29)-NH2. They share a receptor pathway but are different test articles.
How does GHRH signaling differ from ipamorelin?
GHRH peptides activate the pituitary GHRH receptor. Ipamorelin is studied at GHSR, the ghrelin or growth-hormone-secretagogue receptor.
What do the older human papers establish?
They establish GH-axis responsiveness under defined experimental conditions. They do not prove body-composition, recovery, performance, sleep, or anti-aging outcomes.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
A placebo-controlled trial of intranasal growth hormone-releasing hormone [GHRH(1-44)-NH2] administration in normal young adults
- Model
- Human
- Design
- Placebo-controlled experiment in 16 healthy young men comparing defined GHRH(1-44)-NH2 preparations and GH-response measures.
What the paper reported: The study characterized acute GH biomarker responses to the 44-residue amidated hormone under controlled routes and vehicles.
Important limit: Small, old, acute biomarker study; it does not establish a durable health or performance outcome.
Synthetic human growth hormone releasing factor (h-GRF-I-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men
- Model
- Human
- Design
- Randomized-order placebo and response experiment in seven healthy adult men using synthetic hGRF(1-44)-NH2.
What the paper reported: The study described GH biomarker responses across the tested experimental conditions and found no prolactin effect in this small cohort.
Important limit: Seven participants and endocrine markers do not establish clinical efficacy or general safety.
Continuous subcutaneous infusions of growth hormone releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men
- Model
- Human
- Design
- Randomized-order crossover exposure periods in older men with 24-hour GH profiles and IGF-I measurements.
What the paper reported: The study reported changes in GH-pattern and IGF-I biomarkers during controlled short-term GHRH(1-44) exposure.
Important limit: Small specialized cohort, short duration, and hormonal endpoints do not prove anti-aging or functional benefit.
Low-dose growth hormone-releasing hormone tests: a dose-response study
- Model
- Human
- Design
- Randomized-order GHRH(1-29)-NH2 response testing in adult male volunteers with serum-GH measurements.
What the paper reported: The study characterized the shorter amidated fragment's GH-response profile and demonstrates its separate human literature.
Important limit: A diagnostic endocrine-response experiment for GHRH(1-29) cannot be relabeled as evidence for a GHRH(1-44) product.
What the evidence does—and does not—establish
Much of the direct literature is decades old, small, and focused on GH or IGF-I biomarkers. These studies should not be marketed as proof of muscle, fat-loss, recovery, sleep, longevity, or performance outcomes.
GHRH(1-44), GHRH(1-29)/sermorelin, CJC-1295 DAC, modified GRF, and GHSR agonists all interact with the GH axis but are structurally or pharmacologically distinct. Every citation must match the actual listed molecule.
A T44 product needs a disclosed 44-residue sequence, amidation status, salt form, theoretical mass, and observed mass before the full-length GHRH literature can be considered relevant.
- GHRH(1-44) is the full-length hormone studied in the T44 context.
- Sermorelin is the shorter GHRH(1-29)-NH2 fragment.
- Both act at GHRH receptors, not the ghrelin receptor.
- Human studies mostly measured endocrine biomarkers.
- The vendor T44 label needs analytical confirmation.
Where to buy GHRH-T44 / Sermorelin for laboratory research in the USA
A laboratory listing must disclose whether the material is GHRH(1-44)-NH2 or GHRH(1-29)-NH2, then show the full sequence, terminal chemistry, salt form, theoretical and observed mass, labeled quantity, and lot number.
Review the lot-specific COA, chromatogram, test date, storage documentation, fulfillment origin, and support contact. Do not cite 1-29 papers beside a 1-44 product—or the reverse—without an explicit non-equivalence explanation.
Searches such as “where to buy GHRH-T44,” “buy GHRH-T44 USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
GHRH-T44 / Sermorelin research FAQ
What does T44 mean?
It appears to indicate a 44-residue GHRH material, but the product's actual sequence and termini must be confirmed.
Is sermorelin GHRH(1-44)?
No. Sermorelin is GHRH(1-29)-NH2, a shorter active fragment.
Is GHRH-T44 the same as CJC-1295?
No. Published CJC-1295 includes substitutions and DAC albumin-binding chemistry not present in native GHRH(1-44).
Do GH-response studies prove body-composition benefits?
No. Endocrine biomarkers do not establish durable changes in muscle, fat, performance, recovery, or health.
What should a GHRH-T44 COA show?
It should link a specific lot to a disclosed 44-residue sequence, terminal chemistry, observed mass, chromatographic purity, and test date.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Colle M et al. Hormone Research. 1990;33:1-4. PMID 2115856. DOI 10.1159/000181434.
- Boissel JP et al. European Journal of Clinical Pharmacology. 1986;29:609-614. PMID 3082645. DOI 10.1007/BF00635901.
- Corpas E et al. Journal of Clinical Endocrinology & Metabolism. 1993;76:134-138. PMID 8421077. DOI 10.1210/jcem.76.1.8421077.
- Spoudeas HA et al. European Journal of Endocrinology. 1994;131:238-245. PMID 7921207. DOI 10.1530/eje.0.1310238.